This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Haas NB , Giantonio BJ , Litwin S , Minniti CJ , Fox S , Yeslow G , Reilly R , Nahum K , Greenberg R , Halbherr T , Hudes GR
Vinblastine and estramustine phosphate in metastatic renal cell carcinoma - A phase II trial of the fox chase network
Cancer. 2003 Nov;98(9) :1837-1841
AbstractBACKGROUND. It is well known that metastatic renal cell carcinoma (RCC) exhibits constitutive resistance to chemotherapeutic agents. Antimicrotubule agents such as vinblastine are associated with low but reproducible response rates (approximately 12%) in patients with RCC. Estramustine has been shown to potentiate the antimicrotubule effects of vinblastine. The authors sought to increase the activity of vinblastine in RCC through the addition of estramustine. METHODS. Twenty-one patients with metastatic RCC not previously treated with chemotherapy received oral estramustine phosphate, 600 mg/m(2), on Days 1, 2, and 3 weekly for 6 weeks, and intravenous vinblastine, 4 mg/m(2) on Day 2 weekly for 6 weeks, repeated every 8 weeks. Twenty-one patients received 31 cycles of therapy. RESULTS. Two patients experienced Grade 3 and 4 hematologic toxicity, and three patients had Grade 3 nonhematologic toxicity consisting of neurologic toxicity, hepatic toxicity, or angioneurotic edema. One patient had a partial response with decreased liver metastases for 48 weeks; 9 patients had stable disease, for a median duration of 14 weeks (range, 11-31 weeks); and 11 patients demonstrated disease progression. The median overall time to progression was 8 weeks and the median overall survival period was 24 weeks. CONCLUSIONS. Although well tolerated, the combination of oral estramustine phosphate with vinblastine administered on this schedule had minimal activity in patients with metastatic RCC. (C) 2003 American Cancer Society.
NotesEnglish Article Haas, NB; *Fox* *Chase* Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. Research Addresses: *Fox* *Chase* Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. *Fox* *Chase* Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA. *Fox* *Chase* Network Hosp Affiliate, *Fox* *Chase* Canc Ctr, Philadelphia, PA USA. *Fox* *Chase* Canc Ctr, Dept Urol, Philadelphia, PA 19111 USA. Cited References: BATES S, 2001, CANCER, V92, P1577 FOSSA SD, 1994, EUR J CANCER, V30, P1310 FRIDEN B, 1991, BIOCHEM PHARMACOL, V42, P997 GLICK JH, 1980, CANC TREAT REP, V64, P343 HAAS N, 2001, UROLOGY, V58, P59 HAAS N, 1997, CANC CHEMOTHERAPY BI, V17 HAO D, 2000, J CHEMOTHERAPY, V12, P360 HARRIS DT, 1983, SEMIN ONCOL, V10, P422 HUDES G, 1999, J CLIN ONCOL, V17, P3160 HUDES GR, 1992, J CLIN ONCOL, V10, P1754 JEMAL A, 2003, CA-CANCER J CLIN, V53, P5 LAMBE M, 2002, BRIT J CANCER, V86, P1425 MOTZER RJ, 1995, J CLIN ONCOL, V13, P1958 MOTZER RJ, 1999, J CLIN ONCOL, V17, P2530 PANDA D, 1997, P NATL ACAD SCI USA, V94, P10560 PYRHONEN S, 1999, J CLIN ONCOL, V17, P2859 SAMUELS BL, 1997, CLIN CANCER RES, V3, P1977 SPEICHER LA, 1991, BRIT J CANCER, V64, P267 SPEICHER LA, 1992, CANCER RES, V52, P4433 SWANSON DA, 1981, UROLOGY, V17, P344 TEW KD, 1992, PHARMACOL THERAPEUT, V56, P323 YAGODA A, 1989, SEMIN UROL, V7, P199 Number of cited references: 22 Number of times cited: 0 Publisher: JOHN WILEY & SONS INC; 111 RIVER ST, HOBOKEN, NJ 07030 USA. 0008-543X